Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC

  • Check with publisher
  • Published date: November 13, 2017
  • Modified date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4) conjugated via a AcBut linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage. Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.

Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (clone RFB4)-MCC-DM1 ADC

    Anti-CD22 (clone RFB4)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone RFB4) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...

  • Anti-CD22 (10F4v3)-Mc-MMAF ADC

    Anti-CD22 (10F4v3)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...

  • Anti-CD22 (10F4v3)-Mc-VC-PABC-MMAE ADC

    Anti-CD22 (10F4v3)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a Mc-VC-PABC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosi...